Last reviewed · How we verify
Press kit · open data
2026 Phase 3 Readout Tracker
Every Phase 3 trial completing in calendar year 2026, with sponsor, indication, primary endpoint, and whether results are already posted.
Download dataset (CSV) ↓ View interactive tracker →Three headline findings
Finding 1
0 Phase 3 trials complete in 2026
Pulled directly from ClinicalTrials.gov + sponsor disclosures. Filtered to actually-Phase 3 (not "Phase 2/3" — that's a separate dataset on request).
Finding 2
0 already have results posted
Results posted at completion gives the cleanest signal on actual benefit. The rest are tracked monthly; we ping the dataset on every CT.gov results post.
Finding 3
0 distinct sponsors
Concentration matters — sponsor-level cuts available on request. Top 10 sponsors typically account for ~40% of Phase 3 activity.
Cite this dataset
Drug Landscape (2026). 2026 Phase 3 Readout Tracker [Data set]. druglandscape.com. https://druglandscape.com/data/phase-3-readouts-2026.csv
Re-distribution allowed with attribution to druglandscape.com under our editorial policy.
Methodology
Every row in the dataset is sourced from at least one of:
- FDA Drug Approvals Database (Drugs@FDA)
- Sponsor 10-Q / 10-K filings (SEC EDGAR)
- ClinicalTrials.gov NDA/BLA-filing-stage records
- EMA European Public Assessment Reports (EPARs)
- FDA Advisory Committee transcripts
Refresh: nightly. Quality gate: four-point verification — see /editorial-policy for the full pipeline.
Press contact
Drug Landscape press desk
hello@druglandscape.com · about the team
Happy to pull specific cuts of the data (by therapeutic area, sponsor, modality, PDUFA quarter) on request. Usually 24h turnaround.